Combination Therapy with Mitoxantrone and Etoposide in Adult Acute Myelogenous Leukemia
Complete remission (CR) rate in adult acute myelogenous leukemia (AML) was improved by the use of aggressive chemotherapy. Today, more than 70% of patients can achieve a CR [1, 2]. But the relapse rate remains high as well as the rate of failure to therapy in myelodysplasia transformed into overt AML. Moreover, so far the value of aggressive chemotherapy is not clarified in the case of a relapse after intensive treatment like autologous blood stem cell transplantation (ABSCT). Mitoxantrone and etoposide have both been shown to be effective as single agents in the treatment of AML [3-6] and the ability to induce a CR in refractory AML was proven for a combination of the two . We therefore studied the effectiveness of a combination therapy of mitoxantrone and etoposide as first-line therapy in AML, myelodysplasia syndromes (MDSs) transformed into AML, and salvage therapy in AML relapsed after ABSCT.
KeywordsAcute Myeloid Leukemia Complete Remission Acute Leukemia Acute Myelogenous Leukemia Complete Remission Rate
- 1.Büchner T for the AML Cooperative Group (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589Google Scholar